SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Name of Issuer)
Common Stock, Par Value $0.0001 Per Share
(Title of Class of Securities)
December 31, 2018
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d–1(b)
¨ Rule 13d–1(c)
x Rule 13d–1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|CUSIP No. 918640103|
Names of Reporting Persons
The Aberdeen Foundation
|2||Check the Appropriate Box if a Member of a Group
| (a) ¨ |
|3||SEC Use Only|
Citizenship or place of organization
Sole voting power
Shared voting power
Sole dispositive power
Shared dispositive power
Aggregate amount beneficially owned by each reporting person
Check if the aggregate amount in Row (9) excludes certain shares (see instructions) ¨
Percent of class represented by amount in Row (9)
Type of reporting person (See instructions)
* See Item 4(a) below.
** Based on 20,017,248 shares of common stock outstanding as of August 13, 2020, as disclosed in the issuer’s Form 10-Q filed with the SEC on August 14, 2020.
Item 1(a). Name of Issuer:
Item 1(b). Address of Issuer’s Principal Executive Offices:
1895 Mount Hope Avenue, Rochester, New York 14620
Item 2(a). Name of Person Filing:
This Schedule 13G is filed by The Aberdeen Foundation (the “Foundation”).
Item 2(b). Address or principal business office or, if none, residence:
New Burlington House, 1075 Finchley Road, London NW11 0PU, England
Item 2(c). Citizenship:
Item 2(d). Title of class of securities:
Common Stock, par value $0.0001 per share
Item 2(e). CUSIP No.:
Item 3. If this statement is filed pursuant to §§240.13d–1(b) or 240.13d–2(b) or (c), check whether the person filing is a:
Item 4. Ownership
(a) Amount beneficially owned:
As of December 31, 2018, December 31, 2019, and the date hereof, 1,895,580 common shares of the issuer were held by Antibody Investment LLC, a Delaware limited liability company wholly owned by the Foundation. The Foundation is a registered UK Charity. Therefore, the Foundation beneficially owns 1,895,580 common shares of the issuer.
(b) Percent of class: 9.4%
Based on 20,017,248 shares of common stock outstanding as of August 13, 2020, as disclosed in the issuer’s Form 10-Q filed with the SEC on August 14, 2020.
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote: 1,895,580
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to dispose or to direct the disposition of: 1,895,580
(iv) Shared power to dispose or to direct the disposition of: 0
Item 5. Ownership of 5 Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].
Item 6. Ownership of More than 5 Percent on Behalf of Another Person.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
See Exhibit 1 to this statement on Schedule 13G.
Item 8. Identification and Classification of Members of the Group
Item 9. Notice of Dissolution of Group.
Item 10. Certifications
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: October 19, 2020
|THE ABERDEEN FOUNDATION|
|Signed by its authorized Trustee|
|/s/ Michael Shumacher|
|Trustee of the Aberdeen Foundation|
|NAME OF CONTROLLED COMPANY||JURISDICTION OF INCORPORATION||CATEGORY|
|Antibody Investment LLC||Delaware||oo|